New engineered immune cell therapy tested for tough blood cancers
NCT ID NCT07200479
Summary
This is an early-stage study to test the safety and find the right dose of a new CAR-T cell therapy called CT1194D. It is for adults with B-cell blood cancers, like certain lymphomas and leukemias, that have come back or not responded to standard treatments. Researchers will also check how well the modified immune cells work and how long they last in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, 301617, China
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, 301617, China
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, 301617, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.